Cardinal Health Analysts Raise Targets Before Thursday's Print

Cardinal Health trades at $251.54, up 14% over the past month, yet the Street is still adding upside. Mizuho lifted its target to $280 on October 20, and UBS pushed further to $295 the week before, both maintaining positive ratings. The consensus target of $273 implies about 9% additional room from current levels, a gap that is shrinking fast given the recent run.

The analyst direction is unusually uniform going into the October 30 release. Nearly every firm that updated its target after last quarter's print moved it higher: JPMorgan to $260, Barclays to $275, Citigroup, TD Cowen, and Mizuho each to $280. JPMorgan remains the outlier, holding at Neutral while others cluster around Buy and Outperform. The bull case rests on Cardinal's near-unassailable position in pharmaceutical distribution, where it, Cencora, and McKesson control over 90% of the US market, and on the growing contribution from higher-margin businesses including specialty services, biosimilars, and nuclear medicine. Bears counter that the core distribution business runs on wafer-thin gross margins, CVS represents roughly 30% of fiscal 2025 sales, and drug pricing legislation remains an unresolved overhang. The PE has expanded about 2.1 points over the past month to 18.2x, so the market has already repriced some of the optimism.

The positioning data offers little friction to the upside story. Short interest is only 2.95% of the free float, a low reading by any measure, and while it has edged up about 1.9% over the past week, the absolute level gives no real weight to the bear case. Borrow availability is extraordinarily loose at roughly 9,000% of current short interest, meaning there is no pressure in the lending market at all. Cost to borrow has fallen 24% over the past week to 0.33%, reinforcing how uncrowded the short side is. Options positioning is mildly more hedged than usual: the put/call ratio is 0.70 against a 20-day average of 0.67, less than one standard deviation above the mean, which reads as routine caution rather than material concern.

CAH held up better than its closest peers on the week. McKesson was flat, while Cencora dropped nearly 3% over the same period. Wellington Management filed a fresh 13G in August disclosing a 6.3% stake of roughly 14.9 million shares, making it one of the three largest holders alongside BlackRock at 11.4% and Vanguard at around 7%. None of the three registered as activist filers; all disclosures are passive 13G filings, and stakes are as last disclosed around the 5% threshold. The most recent insider activity ran the other way: CEO Jason Hollar sold approximately $9.1 million of stock on August 19, alongside sales by the Chief Legal Officer and Chief Accounting Officer. Those trades were not under 10b5-1 plans, though they now sit ten weeks in the rear view.

The October 30 print will therefore test whether the margin expansion story in specialty and other high-value services is on track to justify a multiple that has moved materially higher, even as the core distribution business faces the pricing and customer-concentration pressures the Street has been watching all year.